VALIDITY OF THE RISK OF MALIGNANCY INDEX IN MALIGNANT OVARIAN TUMOURS

Lt Col (Dr) Bidhan Roy

Abstract


INTRODUCTION:
Ovarian cancer accounts for 5 to 8 % of all gynaecological
malignancies. It has the highest case-fatality ratio of all gynaecological
malignancies. A high index of suspicion, better screening modalities
and recognition of high risk factors help to detect ovarian malignancy
earlier [1]. Risk of malignancy index is able to correctly discriminate
between malignant and benign neoplasm of ovary. It is a scoring
system which can be introduced easily into clinical practice to
facilitate the selection of the patient for primary surgery at an
oncological unit .RMI in ovarian malignancy incorporates CA-125,
USG and Menopausal status for the accurate pre-operative diagnosis
of ovarian cancer. RMI is useful in deciding if an ovarian mass is
malignant or benign, screening for suspected pelvic mass, deciding
appropriate management protocol and triaging management [2].


Full Text:

PDF

References


Bereck J S, Hacker NF. Practical Gynaecologic Oncology; 5th Edition, Philadelphia. Lippioncott Williams & Wilkins 2012; 3: 38.

Ian Jacobs, Davis A.P. The adnexal mass – benign or malignant? Evaluation of the risk of malignant index. British Journal of Obstet & Gynaecology 1993;100:927-31.

Menon U, Stakes S J, Lewis .Prospective study using the risk of ovarian cancer. J. Clin. Oncol 2005; 23 :7919 –7926.

Baron A T, Broadman C H , Lafky J M .Soluble epidermal growth factor receptor and cancer antigen as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers 2005; 14 : 306-318.

Sassone A M, Timor E, Artner A Transvaginal sonographic characterization of the ovarian disease- evaluation of a new scoring system to predict ovarian malignancy. Obst & Gynae 2001;78:70-76.

De Priest P D , Shenson D , Fried A . A morphologic index based on sonographic findings in ovarian cancer .Gynaecol – Oncol 1993; 51: 7 -11.

Alcazar J L , Merce L T , Laparte C . A morphologic index based on sonographic findings in ovarian cancer. Gynaecol – Oncol 1993; 51: 7 –11.

Jacobs I, Bast RC Jr. The CA 125 tumour associated antigen: A review of the literature. Human Reprod.1989; 4: 1-12.

Jacob I, Pyrs Davies A, Bridges J, et al. Prevelance screening for ovarian cancer in post-menopausal women by CA 125 measurement and ultrasonography. BMJ.1993; 306: 1030-34.

Lerner J P, Timor Tritsh I E, Monteagado A etal. Transvaginal ultrasonographic characterization of ovarian mass by means of colour flow directed doppler measurements and a morphologic scoring system. Am J obstet Gynaecol 1993; 168: 909 -13.

Ferrazi E, Zanetta G, Dordoni D, Brrlanda N , Mezzopnae R, Lissoni A . Transvaginal ultrasonographic characterization of five scoring systems in a multicenter study ultrasound Obstet Gynaecol 1997;10:192-97.

Buys S S, Partridge E, Greene M H, et al. PCLO Project team. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynaecol;

:1630-1639.

Partridge E, Greene M H .PCLO Project team. Ovarian cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial: finding from the initial screen of a randomized trial; Am J of Obstet Gynaecol; 193: 1630-1639.

http: // www.ukctocs.org.uk.


Refbacks

  • There are currently no refbacks.